Trial Profile
AMBITION: A Randomised, Multicenter Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)
Status:
Completed
Phase of Trial:
Phase III/IV
Latest Information Update: 01 Sep 2023
Price :
$35
*
At a glance
- Drugs Ambrisentan (Primary) ; Tadalafil (Primary)
- Indications Pulmonary arterial hypertension
- Focus Registrational; Therapeutic Use
- Acronyms AMBITION
- Sponsors Gilead Sciences; GlaxoSmithKline; GSK
- 19 Nov 2020 Results comparing effectiveness of macitentan versus ambrisentan in monotherapy and combination therapy, utilizing Bucher's indirect treatment comparison (ITC) method with individual patient data from the SERAPHIN study and aggregate data from the AMBITION study, presented at the 23rd Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research.
- 16 Sep 2020 Results of pooled analysis of three studies (AMBITION, SERAPHIN, and GRIPHON) comparing validated clinical scales of risk (COMPERA, the French score, and REVEAL 2.0) to identify patients that are likely to experience a clinical worsening event for trial enrichment, published in the American Journal of Respiratory and Critical Care Medicine.
- 01 Sep 2020 Results of post-hoc analysis (n=605) presented at the ESC Congress 2020 - Annual Congress of the European Society of Cardiology